[1] XU J J， HENSTOCK P V， DUNN M C， et al. Cellular imaging predictions of clinical drug-induced liver injury[J]. Toxicol Sci， 2008， 105(1：97-105.
[2] MARRER E， DIETERLE F. Impact of biomarker development on drug safety assessment[J]. Toxicol Appl Pharmacol， 2010， 243(2：167-179.
[3] OZER J， RATNER M， SHAW M， et al. The current state of serum biomarkers of hepatotoxicity[J]. Toxicology， 2008， 245(3：194-205.
[4] YANG R Z， PARK S， REAGAN W J， et al. Alanine aminotransferase isoenzymes： molecular cloning and quantitative analysis of tissue expression in rats and serum elevation in liver toxicity[J]. Hepatology， 2009， 49(2：598-607.
[5] MIYAZAKI M， ROSENBLUM J S， KASAHARA Y， et al. Determination of enzymatic source of alanine aminotransferase activity in serum from dogs with liver injury[J]. J Pharmacol Toxicol Methods， 2009， 60(3：307-315.
[6] O′BRIEN P J， SLAUGHTER M R， POLLEY S R， et al. Advantages of glutamate dehydrogenase as a blood biomarker of acute hepatic injury in rats[J]. Lab Anim， 2002， 36(3：313-321.
[7] LEE W K， SHIN S， CHO S S， et al. Purification and characterization of glutamate dehydrogenase as another isoprotein binding to the membrane of rough endoplasmic reticulum[J]. J Cell Biochem， 1999， 76(2：244-253.
[8] MULLER P Y， DIETERLE F. Tissue-specific， non-invasive toxicity biomarkers： translation from preclinical safety assessment to clinical safety monitoring[J]. Expert Opin Drug Metab Toxicol， 2009， 5(9：1023-1038.
[9] BECKETT G J， FOSTER G R， HUSSEY A J， et al. Plasma glutathione-S-transferase and F protein are more sensitive than alanine aminotransferase as markers of paracetamol (acetaminophen-induced liver damage[J]. Clin Chem， 1989， 35 (11：2186-2189.
[10] REES G W, TRULL A K, DOYLE S. Evaluation of an enzyme-immunometric assay for serum alpha-glutathione S-trsansferase[J]. Ann Clin Biochem， 1995, 32（6：575-583.
[11] RAMAIAH S K. A toxicologist guide to the diagnostic interpretation of hepatic biochemical parameters[J]. Food Chem Toxicol， 2007， 45(9：1551-1557.
[12] WRIGHT T M， VANDENBERG A M. Risperidone- and quetiapine-induced cholestasis[J]. Ann Pharmacother， 2007， 41(9：1518-1523.
[13] SENIOR J R. Monitoring for hepatotoxicity： what is the predictive value of liver "function" tests?[J]. Clin Pharmacol Ther， 2009， 85(3： 331-334.
[14] FABRIS L， CADAMURO M， OKOLICSANYI L. The patient presenting with isolated hyperbilirubinemia[J]. Dig Liver Dis， 2009， 41(6：375-381.
[15] MURAYAMA H， IKEMOTO M， FUKUDA Y， et al. Advantage of serum type-I arginase and ornithine carbamoyltransferase in the evaluation of acute and chronic liver damage induced by thioacetamide in rats[J]. Clin Chim Acta， 2007， 375(1-2：63-68.
[16] KAWAI M, HOSAKI S. Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease [J]. Clin Biochem, 1990, 23(4:327-334.
[17] MISRA M K， KHANNA A K， SHARMA R， et al. Serum malate dehydrogenase (MDH in portal hypertension its value as a diagnostic and prognostic indicator[J]. Indian J Med Sci，1991， 45(2：31-34.
[18] ZIEVE L, ANDERSON W R, DOZEMAN R, et al. Acetaminophen liver injury: sequential changes in two biochemical indices of regeneration and their relationship to histologic alterations [J]. J Lab Clin Med, 1985, 105(5:619-624.
[19] KORSRUD G O, GRICE H C, MCLAUGHLAN J M. Sensitivity of several serum enzymes in detecting carbon tetrachloride-induced liver damage in rats [J]. Toxicol Appl Pharmacol, 1972, 22(3:474-483.
[20] OHUCHI T, TADA K, AKAMATSU K. Endogenous ET-1 contributes to liver injury induced by galactosamine and endotoxin in isolated perfused rat liver [J]. Am J Physiol, 1995, 268(6 Pt 1:G997-1003.
[21] MOCHIDA S， ARAI M， OHNO A， et al. Deranged blood coagulation equilibrium as a factor of massive liver necrosis following endotoxin administration in partially hepatectomized rats[J]. Hepatology， 1999， 29(5：1532-1540.
[22] FUKUDA M， YOKOYAMA H， MIZUKAMI T， et al. Kupffer cell depletion attenuates superoxide anion release into the hepatic sinusoids after lipopolysaccharide treatment[J]. J Gastroenterol Hepatol， 2004， 19(10：1155-1162.
[23] NG C J， BOURQUARD N， GRIJALVA V， et al. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins： anti-atherogenic role for paraoxonase-2[J]. J Biol Chem， 2006， 281(40：29491-29500.
[24] MENESES-LORENTE G， GUEST P C， LAWRENCE J， et al. A proteomic investigation of drug-induced steatosis in rat liver[J]. Chem Res Toxicol， 2004， 17(5：605-612.
[25] ADLER M， HOFFMANN D， ELLINGER-ZIEGELBAUER H， et al. Assessment of candidate biomarkers of drug-induced hepatobiliary injury in preclinical toxicity studies[J]. Toxicol Lett， 2010， 196(1：1-11.
[26] SHI Q， HONG H， SENIOR J， et al. Biomarkers for drug-induced liver injury[J]. Expert Rev Gastroenterol Hepatol， 2010， 4(2：225-234.
[27] CORTEZ M A， CALIN G A. MicroRNA identification in plasma and serum： a new tool to diagnose and monitor diseases[J]. Expert Opin Biol Ther， 2009， 9(6：703-711.
[28] SAHA B， NANDI D. Farnesyltransferase inhibitors reduce ras activation and ameliorate acetaminophen-induced liver injury in mice[J]. Hepatology， 2009， 50(5： 1547-1557.
[29] BEGER R D， SUN J， SCHNACKENBERG L K. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity[J]. Toxicol Appl Pharmacol， 2010， 243(2：154-166.
[30] LEE M S， JUNG B H， CHUNG B C， et al. Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine[J]. Int J Toxicol， 2009， 28(5：392-404.